Background: Congenital myasthenic syndrome (CMS) due to mutations in GMPPB has
ophthalmoplegia or facial weakness, and links myasthenic disorders with dystroglycanopathies. This report should facilitate the recognition of this disorder, which is likely to be under-diagnosed and can benefit from symptomatic treatment.
INTRODUCTION
Congenital myasthenic syndromes (CMS) are disorders caused by mutations in genes encoding proteins that are essential for maintaining the integrity of neuromuscular transmission [1] . All syndromes share the clinical features of fatigable weakness, but age at onset, presenting symptoms, distribution of weakness, and response to treatment vary depending on the molecular mechanism resulting from the genetic defect. At present, mutations in at least 21 different genes are known to cause CMS [2] . Most of these genes encode proteins with a direct role in neuromuscular transmission such as the acetylcholine receptor (AChR) subunits and in the development or maintenance of the NMJ integrity such as DOK7 [3, 4] . More recently, an unexpected relationship between defects in the glycosylation of proteins and CMS was found by using next-generation sequencing technology [5] [6] [7] . Mutations in ALG2, ALG14 [5] , DPAGT1 [6] and GFPT1 [7] were shown to produce a CMS with a predominantly limb girdle pattern of muscle weakness and minimal facial and ocular involvement.
Glycosylation is a ubiquitous pathway defined by the sequential attachment of sugar moieties to the polypeptide backbone ( Figure 1 ). Post-translational modification of proteins is crucial for protein folding, transport and functionality [8] . In CMS, one suggested mechanism is through glycosylation of AChR subunits, which is required for the correct assembly of AChR pentamers and for efficient export to the cell surface [9] and so, abnormal glycosylation results in a reduction of AChRs at the muscle endplates and a reduced synaptic response to acetylcholine [7] . Many other key NMJ proteins such as MuSK, agrin, integrins and neural cell adhesion molecules (NCAM) are also glycosylated [10] and therefore their abnormal glycosylation could contribute to the pathogenic effect. It is not known why defects in this ubiquitous process result in a dysfunction mainly restricted to the NMJ.
GMPPB is a recently reported CMS-associated gene [11] . GMPPB encodes GDPmannose pyrophosphorylase B that catalyzes the conversion of mannose-1-phosphate and GTP to GDP-mannose. GMPPB contributes to both the N-glycosylation and the Omannosylation pathways (Figure 1) . Mutations within the O-mannosylation pathway were originally identified in patients with a form of muscular dystrophy within the spectrum of dystroglycanopathies [12] . These disorders are characterized by reduction in α-dystroglycan glycosylation, which is the most well characterized and functionally relevant O-mannosylated protein. Patients with autosomal recessive mutations in GMPPB had reduced glycosylation of α-dystroglycan in skeletal muscle and variable degree of clinical severity ranging from congenital muscular dystrophies with associated structural brain involvement, to milder limb-girdle muscular dystrophy variants of late childhood onset [13] . Recently, we showed that autosomal recessive mutations in GMPPB can also cause CMS and bridge myasthenic disorders with dystroglycanopathies [11] . This increased the spectrum of disorders caused by GMPPB mutations and confirmed the importance of glycosylation for the integrity of neuromuscular transmission.
Here we describe in detail the clinical features and investigation results of eight patients with CMS due to mutations in GMPPB and investigate CMS syndrome-specific CK values within our cohort to confirm its usefulness in the differential diagnosis.
METHODS
Next-generation sequencing and Sanger screening identified the underlying genetic mutations in GMPPB in 8 individuals from 6 different kinships (Table 1) 
RESULTS

Clinical features
Clinical presentation
Pregnancy and early-life features were uneventful in all patients except in case 4 with congenital hip dislocation and resulting delayed motor milestones. None of the patients were ventilated as infants or had feeding difficulties. The median age of onset was 22 years (range 1.5 -50 years). Case 1 presented at age 24 years with limited walking tolerance following an influenza illness. Previously her gait was unrestricted.
Case 2 was unable to run during her teens and had lumbar hyperlordosis noted from her 20s. Case 3 was unable to get up off the floor and had difficulty lifting heavy objects at age 20 years. She also had decreased walking tolerance and had to rest after 5 minutes of walking. Case 4 had difficulty climbing-up ramps and walking long distances noted from her mid-20s. Case 5 presented at 18 months with an acute episode of generalised weakness and persistently raised CK. Subsequently, she remained clumsier and slow at school compared to peers. Cases 6-8 presented with gait disturbance (waddling), difficulty climbing stairs and muscle cramps at the ages of 16, 22 and 31 years, respectively. Of note, even though most patients had onset in adult life, they recall being slower than peers at school and not good at sports.
Pattern of weakness at assessment
All patients had a predominantly limb-girdle pattern of muscle weakness, which was more severe in the lower than in the upper limbs, with moderate to severe impairment and marked waddling gait in some cases. Mild distal weakness was present only in cases 5 and 8. Facial and eye movements were normal in all patients, and only case 6 had mild fatigable ptosis. Two patients complained of occasional double vision (cases 2 and 6), although no ophthalmoparesis was elicited during examination. Neck muscles were mild to moderately weak in 4 patients without manifest flexor/extensor preponderance. Axial weakness was present in 6 patients with moderate to severe lumbar hyperlordosis in 5. Mild swallowing difficulties, in the absence of speech abnormalities, were reported by case 7. Only case 2 suffered from shortness of breath on exertion, although there was a background history of asthma. None of the patients have required respiratory support.
Additional clinical features
Episodes of muscle aches and cramps were reported (case 3, 5 and 6-8), mainly in the calves, and activity-induced, such as with walking. Cramps were occasional but variable in frequency depending on the period, and usually subsided by extending the affected muscle. Case 4 had hypertrophic calves and thighs on physical examination. Case 5 was diagnosed with cataracts aged 9. Contractures were found only in case 5 with tightness of Achilles tendons bilaterally. Unlike other myasthenic syndromes, most of the patients did not have easily demonstrable short-term fatigability of muscle strength.
Case 3 had mild learning difficulties in school. None of the patients had known cardiac involvement.
Course of disease
The long-term course of disease was generally progressive with gradual deterioration in muscle strength and mobility over time. In addition, there were significant deteriorations during intercurrent illnesses. Case 1 currently walks only for short distances with assistance and requires physical assistance in terms of activities of daily living and self-care. Case 2, with onset in her teens, has been unable to climb stairs for the last decade, and has difficulties in standing from a seated position. Although she could lift loads during her adult life, she developed significant proximal arm weakness in her fifth decade. Case 3 is currently stable on treatment, and mainly finds it difficult to hold heavy objects and walk long distances. Case 4 had a slowly progressive deterioration of her waddling gait, with more recent requirement of a walking stick.
Case 5 gradually deteriorated during childhood and adolescence with proximal weakness and mobility problems. Prior to treatment, she had limited walk tolerance, and on a bad day she could only walk around the house and used a wheelchair for distance. Cases 6-8 still walk independently although have had progressive deterioration in their gait over the years. Fluctuations of muscle strength over the course of days and weeks were reported in cases 1-5. They were commonly related to intercurrent viral infections, although they also occurred following no particular precipitant (case 1 and 5). Cases 3, 4 and 6 reported significant worsening of symptoms with menstruation. Case 6 also reported worsening of symptoms during pregnancy.
Response to treatment
All patients treated with pyridostigmine had a positive response to treatment. The effect was notable in cases 1,3,5,6,7 and 8 but mild in cases 2 and 4. Case 3 increased her endurance so that she can walk up to 10 minutes without fatigue and is able to manage stairs at home independently. She recalls omitting her medication by accident on a few occasions and being much weaker afterwards. For Case 4, walking improved such that she stopped using her walking stick. Her proximal strength in the upper and lower limbs is now graded MRC 5 from a previous MRC score of 4. Case 5 reported improvement in her muscle strength and walking speed, with less fatigability and reduced wheelchair use. After pyridostigimine, Case 6 improved her long distance walking and improvements of ptosis and dysphagia were noted. Cases 1 reported additional benefit from 3,4-DAP (30 mg/day) and salbutamol (0.1 mg/Kg/day), and cases 2 and 4 reported benefit from additional salbutamol ( 0.05-0.2 mg/Kg/day).
Investigations
Neurophysiology
All patients had findings consistent with abnormal neuromuscular transmission on electrophysiological testing (Table 2) Muscle biopsy Cases 1, 3, 4, and 5 underwent muscle biopsy (Table 2 ). All cases showed dystrophic features and reduced labeling for -dystroglycan when immunohistochemical staining was performed. Secondary reduction of laminin-2 chain on immunoblotting was noted in case 3 and 4. Cases 3 and 5 showed sparse inflammation and focal upregulation of MHC-I complex, mostly within regenerating fibres. Tubular aggregates, which have previously been described in some forms of CMS due to glycosylation pathway defects, were not found in any of the samples. The muscle biopsy from case 3 is described in detail in Figure 3A -I.
Muscle MRI
Muscle MRI from cases 2 and 4, at age 66 and 42 years respectively, showed extensive changes in T1-weighted sequences in pelvis and thighs, with predominant involvement of the posterior compartment of the thighs and relative sparing of certain muscle groups ( Figure 4A-B) . Case 2 had MRI of the calves that showed additional involvement 11 . Case 5 had a normal muscle MRI at age 10 years.
Serum CK
We reviewed the serum CK values of 133 available patients with CMS ( Figure 5 ). All GMPPB-CMS patients tested had raised creatine kinase levels in serum (2350 ± 660 UI/L; range 418-4807 UI/L). The mean serum CK value of GMPPB-CMS patients was 10.74 times above the upper limit of normal and was significantly higher than in any other CMS subtype (one-way ANOVA; P<0.001, Dunnett's multiple comparison test).
Occasionally, patients with DOK7-CMS, Slow Channel Syndrome and GFPT1-CMS had modestly raised CK values. pyridostigmine and the dystrophic changes on muscle biopsy. Slow channel syndrome [15] and DOK7-CMS [16] can have a myopathic component with non-specific changes on muscle biopsy (such as increased variation in fibre size and core-like areas) and mildly raised CK levels, but these are rarely above 5 times the upper limit of normality.
DISCUSSION
Cramps can also be seen in patients with DOK7-CMS, and may worsen on treatment with ß2-adrenergic agonists.
CMS due to other glycosylation pathway defects (GFPT1 [7] , DPAGT1 [17] and ALG2/14 [5] ) have clinical similarities to GMPPB-CMS, including clinical presentation, pattern of weakness, and response to treatment. However, GMPPB-CMS has a greater degree of myopathic involvement as shown by the higher CK levels and dystrophic changes on muscle biopsy. This is likely due to the additional role of GMPPB in the Omannosylation pathway and glycosylation of α-dystroglycan. GFPT1, DPAGT1 and ALG2-CMS can have tubular aggregates on muscle biopsy [18] . These have not been detected in GMPPB-CMS although electron microscopy, which is a more sensitive method to detect tubular aggregates, was only performed in one case. GFPT1-CMS can display modestly raised CK values [19] but in our experience these are not as high as seen in GMPPB-CMS. Extensive abnormalities in muscle MRI have also been seen in GFPT1, DPAGT1 and ALG2/14-CMS, but not consistently in the more common CMS subtypes, although some patients with slow channel syndrome and DOK7 and RAPSN mutations can show a wide range of fatty infiltration [20] . It is, therefore, understandable that most of these disorders were classified previously as non-specific myopathies. Cases 3 and 5 were initially misdiagnosed as autoimmune myopathies and treated with immunosuppression without improvement. Serum CK levels are significantly higher in patients with GMPPB-CMS, and so will be helpful in the differential diagnosis. Biochemical studies of transferrin glycosylation on serum samples have been found to be abnormal in only a few of our patients with DPAGT1 mutations [17] , but could be abnormal in GMPPB-CMS. However we believe that a combination of decrement of CMAP with repetitive nerve stimulation on EMG with measurement of serum CK will give simpler and better diagnostic pointer.
We have not seen heart abnormalities in 3 patients with GMPPB-CMS undergoing cardiac studies. However, a small study showed mild cardiac abnormalities in CMS patients with mutations in GFPT1 and DPAGT1, including abnormal Of note, GMPPB is involved in the O-mannosylation pathway, which is required for the glycosylation of α-DG, and thus is of special relevance to the dystroglycanopathies.
DOLK, dolichol kinase; DPM, dolichol-phosphate mannose synthase; Fru-6-P, fructose-6-phosphate; GlcN-6-P, glucosamine-6-phosphate; Glu-6-P, glucose-6-phosphate. Numbers of patients included from each CMS category are displayed in brackets. The Treatment P, D, S P, S P P, S P P P P Footnote: D, 3,4-DAP; LL, lower limbs; P, pyridostigmine; S, salbutamol; UL, upper limbs. * Ptosis appeared at age 26 after developing thyrotoxicosis and receiving treatment for it. 
